Natera, Inc. (NASDAQ:NTRA) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 51.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 86,199 shares of the medical research company's stock after selling 90,960 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.07% of Natera worth $5,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. RiverPark Advisors LLC purchased a new position in shares of Natera during the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Natera in the third quarter worth $44,000. CWM LLC grew its stake in shares of Natera by 224.4% in the third quarter. CWM LLC now owns 1,317 shares of the medical research company's stock worth $58,000 after acquiring an additional 911 shares during the last quarter. Captrust Financial Advisors grew its stake in shares of Natera by 186.4% in the second quarter. Captrust Financial Advisors now owns 2,248 shares of the medical research company's stock worth $80,000 after acquiring an additional 1,463 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Natera by 215.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company's stock valued at $83,000 after purchasing an additional 1,399 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research reports. StockNews.com cut Natera from a "hold" rating to a "sell" rating in a research report on Thursday, March 14th. Sanford C. Bernstein raised Natera from a "market perform" rating to an "outperform" rating and set a $120.00 target price on the stock in a research report on Friday, April 5th. The Goldman Sachs Group raised their target price on Natera from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Monday. BTIG Research raised their target price on Natera from $75.00 to $85.00 and gave the stock a "buy" rating in a research report on Friday, December 29th. Finally, Canaccord Genuity Group lifted their price objective on Natera from $87.00 to $100.00 and gave the company a "buy" rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $86.40.

Natera Price Performance

NTRA traded down $0.10 on Tuesday, hitting $90.32. 1,389,466 shares of the company's stock traded hands, compared to its average volume of 1,480,845. The company's 50 day simple moving average is $84.98 and its 200-day simple moving average is $65.24. The firm has a market cap of $10.91 billion, a price-to-earnings ratio of -23.83 and a beta of 1.37. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. As a group, research analysts anticipate that Natera, Inc. will post -2.35 EPS for the current year.

Insider Transactions at Natera

In related news, insider John Fesko sold 2,358 shares of the business's stock in a transaction on Monday, January 29th. The stock was sold at an average price of $65.09, for a total transaction of $153,482.22. Following the completion of the transaction, the insider now owns 108,494 shares in the company, valued at approximately $7,061,874.46. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Natera news, insider Jonathan Sheena sold 26,700 shares of the company's stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $92.47, for a total value of $2,468,949.00. Following the completion of the sale, the insider now directly owns 321,031 shares in the company, valued at approximately $29,685,736.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John Fesko sold 2,358 shares of the company's stock in a transaction on Monday, January 29th. The stock was sold at an average price of $65.09, for a total value of $153,482.22. Following the completion of the sale, the insider now owns 108,494 shares of the company's stock, valued at $7,061,874.46. The disclosure for this sale can be found here. In the last 90 days, insiders sold 366,477 shares of company stock worth $28,552,682. 9.42% of the stock is currently owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.